Melanoma News and Research

Latest Melanoma News and Research

Study on papillary thyroid carcinoma to be presented at 84th Annual Meeting of the ATA

The prevalence of papillary thyroid carcinoma (PTC), the most common type of thyroid cancer, is increasing rapidly. New research to determine the impact of radioactive iodine (RAI) therapy on survival in PTC, describing a novel blood test able to detect circulating BRAFV600E-positive tumor DNA, and identifying a long non-coding RNA specifically associated with the thyroid that is down-regulated in PTC compared to normal thyroid tissue in patient-derived clinical specimens and cell cultures will be featured in oral presentations delivered at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California.

30 Oct 2014

Researchers reveal how particular melanoma cells help tumors resist drugs

UNC School of Medicine researchers have pinpointed a set of intriguing characteristics in a previously unknown subpopulation of melanoma cancer cells in blood vessels of tumors. These cells, which mimic non-cancerous endothelial cells that normally populate blood vessels in tumors, could provide researchers with another target for cancer therapies.

25 Oct 2014

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen Research & Development, LLC today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc.

20 Oct 2014

Ebola outbreak emphasizes the importance of monitoring disease burden in developing countries

A study recently published in the Journal of the American Academy of Dermatology shows that for Ebola, measles, syphilis and many other conditions with skin manifestations the mortality rates are hundreds of times higher in developing countries than they are in developed countries.

16 Oct 2014

Melanoma cells create own 'green light' signal to spread in the body

CANCER RESEARCH UK scientists have discovered that melanoma cells are drawn to follow the 'trail' of a naturally-occurring molecule in the body, which directs this serious type of skin cancer to spread, according to research published today (Tuesday) in PLOS Biology.

15 Oct 2014

New research may help identify individuals at increased risk of pancreatic cancer

New research that provides a better understanding of pancreatic cancer may help identify individuals at increased risk. The findings are published early online in Cancer, a peer-reviewed journal of the American Cancer Society.

15 Oct 2014

Blocking STAT3 in immune system cells increases anti-tumour immunity

The STAT transcription factors are involved in the development of many forms of cancer. STAT3 is frequently activated in tumour cells, so drugs targeting STAT3 could be used in cancer therapy. However, STAT3 is also important in the development of the immune system. Dagmar Gotthardt and colleagues at the Vetmeduni Vienna now show that blocking STAT3 in cells of the immune system actually leads to increased anti-tumour immunity. Anti-STAT3 therapy may thus be highly promising.

13 Oct 2014

RNA molecules in tissue, urine samples can detect prostate cancer

Researchers at Sanford-Burnham Medical Research Institute have identified a set of RNA molecules that are detectable in tissue samples and urine of prostate cancer patients but not in normal healthy individuals.

10 Oct 2014

GE Healthcare-Glaxo Smith Kline deal to create force in cancer testing

A recently announced deal between GE Healthcare-subsidiary Clarient and Glaxo Smith Kline will create a force in cancer testing, according to Kalorama Information. The healthcare market research publisher tracks companion products, and says that the two entities will form a multi-purpose, data analytics- and companion diagnostics-driven network of laboratories. Kalorama Information recently released a market study, Companion Diagnostics Market, for companion diagnostics such as the drug-test combinations envisioned in this deal.

9 Oct 2014

NIH announces high-risk, high-reward grants for UCSF researchers

UC San Francisco researchers received five awards announced this week by the National Institutes of Health (NIH) for high-risk, high-reward scientific research projects. Their work will focus on novel approaches for diagnosing and treating diseases ranging from autoimmune and chronic inflammatory diseases, to cancer, diabetes and neurological disorders.

8 Oct 2014

Cancer Network presents exclusive coverage of ESMO 2014 Congress

UBM Medica US announces that Cancer Network, a leading online community for oncologists and others who treat cancer and the online home of the journal ONCOLOGY, presents exclusive coverage of the European Society for Medical Oncology (ESMO) 2014 Congress, held September 26–30 in Madrid, Spain.

8 Oct 2014

UCSF researchers receive five NIH awards for high-risk scientific research projects

UC San Francisco researchers received five awards announced this week by the National Institutes of Health for high-risk, high-reward scientific research projects. Their work will focus on novel approaches for diagnosing and treating diseases ranging from autoimmune and chronic inflammatory diseases, to cancer, diabetes and neurological disorders.

8 Oct 2014

Gigapixel whole-body photographic camera may help doctors spot cancer early, save lives

Melanoma is the fifth most common cancer type in the United States, and it's also the deadliest form of skin cancer, causing more than 75 percent of skin-cancer deaths. If caught early enough though, it is almost always curable. Now a camera, capable of taking snapshots of the entire human body and rendering high-resolution images of a patient's skin may help doctors spot cancer early and save lives.

7 Oct 2014

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies.

6 Oct 2014

Cultural, historical forces contribute to rise in cases of melanoma

A century's worth of cultural and historical forces have contributed to the rise in the incidence of melanoma, including changes in fashion and clothing design, according to an intriguing, retrospective research study conducted by investigators in the Ronald O. Perelman Department of Dermatology at NYU Langone Medical Center.

3 Oct 2014

MD Anderson's James P. Allison to receive 2014 Louisa Gross Horwitz Prize for work on immunotherapy

Columbia University will award the 2014 Louisa Gross Horwitz Prize to James P. Allison, PhD, of the University of Texas MD Anderson Cancer Center, for his work on understanding the process of T-cell activation and for developing therapies that harness the immune system to fight cancer.

3 Oct 2014

Combination treatment prevents disease progression in patients with advanced melanoma

New data announced today has demonstrated that combinational treatment of cobimetinib with Zelboraf (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone.

30 Sep 2014

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

GSK today announced updated results for Tafinlar (dabrafenib) from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma.

30 Sep 2014

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.

30 Sep 2014

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Melanoma News and Research

Latest Melanoma News and Research

Study on papillary thyroid carcinoma to be presented at 84th Annual Meeting of the ATA

Researchers reveal how particular melanoma cells help tumors resist drugs

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Ebola outbreak emphasizes the importance of monitoring disease burden in developing countries

Melanoma cells create own 'green light' signal to spread in the body

New research may help identify individuals at increased risk of pancreatic cancer

Blocking STAT3 in immune system cells increases anti-tumour immunity

RNA molecules in tissue, urine samples can detect prostate cancer

GE Healthcare-Glaxo Smith Kline deal to create force in cancer testing

NIH announces high-risk, high-reward grants for UCSF researchers

Cancer Network presents exclusive coverage of ESMO 2014 Congress

UCSF researchers receive five NIH awards for high-risk scientific research projects

Gigapixel whole-body photographic camera may help doctors spot cancer early, save lives

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

Cultural, historical forces contribute to rise in cases of melanoma

MD Anderson's James P. Allison to receive 2014 Louisa Gross Horwitz Prize for work on immunotherapy

Combination treatment prevents disease progression in patients with advanced melanoma

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Melanoma News and Research

Latest Melanoma News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in